comparemela.com
  1. Home
  2. Live Updates
  3. Accutar Biotechnology Inc - Breaking News

Latest Breaking News On - Accutar biotechnology inc - Page 1 : comparemela.com

Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024

CRANBURY, N.J. (BUSINESS WIRE) Jun 1, 2024

United statesJiaqi renAccutar biotechnology incAmerican society of clinical oncologyAmerican societyClinical oncologyAnnual meetingDevelopmental therapeuticsMolecularly targeted agentsLijie fanChief executive officerAccutar biotechnologyBusiness wire

Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study in Patients with Relapsed/Refractory B-cell Malignancies

Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study in Patients with Relapsed/Refractory B-cell Malignancies
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Accutar biotechnology incChimeric degrader withDifferentiated mechanismRemoving both kinase and scaffolding functionsCoverage designedOvercome resistanceCovalent and nonAccutar biotechnologyTyrosine kinaseLijie fanChief executive officerProtein interaction targeting chimeraChronic lymphocytic leukemiaSmall lymphocytic lymphomaLargeb cell lymphomaMantle cell lymphoma

Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study in Patients with Relapsed/Refractory B-cell Malignancies

Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study in Patients with Relapsed/Refractory B-cell Malignancies
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jiaqi renAccutar biotechnology incChimeric degrader withDifferentiated mechanismRemoving both kinase and scaffolding functionsCoverage designedOvercome resistanceCovalent and nonTyrosine kinaseLijie fanChief executive officerAccutar biotechnologyProtein interaction targeting chimeraChronic lymphocytic leukemiaSmall lymphocytic lymphomaLargeb cell lymphoma

Stock Market | FinancialContent Business Page

Stock Market | FinancialContent Business Page
financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.

Accutar biotechnology incChimeric degrader withDifferentiated mechanismRemoving both kinase and scaffolding functionsCoverage designedOvercome resistanceCovalent and nonTyrosine kinaseLijie fanChief executive officerAccutar biotechnologyProtein interaction targeting chimeraChronic lymphocytic leukemiaSmall lymphocytic lymphomaLargeb cell lymphomaMantle cell lymphoma

Clinical Trial: AC699 in ER+, HER2- Advanced Breast Cancer

Researchers are conducting a phase 1 trial to test AC699 in patients with ER+, HER2- locally advanced or metastatic breast cancer.

Accutar biotechnology incAccutar biotechnology

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.